Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BBV152A (Bharat Biotech)
- Development stage
- Unknown
- Lead developer
- Bharat Biotech
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
BBV152A is a specific formulation of the whole-virion inactivated SARS-CoV-2 vaccine, COVAXIN, developed by Bharat Biotech International Limited in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV). It consists of inactivated SARS-CoV-2 antigen (strain NIV-2020-770) adsorbed to aluminum hydroxide gel (Algel) and is formulated with a novel Toll-like receptor 7/8 (TLR 7/8) agonist, imidazoquinolin gallamide (IMDG). This adjuvant system, known as Algel-IMDG, is designed to enhance the immune response and induce a T-helper-1 (Th1) skewed response, which is associated with reduced risk of vaccine-associated enhanced respiratory disease. BBV152A was evaluated in Phase 1 and Phase 2 clinical trials, where it demonstrated superior immunogenicity compared to other formulations, leading to its selection for further development for the prevention of COVID-19.
- Brand names
- COVAXIN
- Other names
- BBV152BBV-152BBV 152
02
Targets
TLR8 (Toll-like receptor 8)TLR7 (Toll-like receptor 7)
Beyond the preview
Go deeper on BBV152A (Bharat Biotech).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BBV152A (Bharat Biotech).